LuMind IDSC Foundation

Have you heard? We are proud to be a sponsor of the 2024 National Down Syndrome Society Adult Summit taking place November 14-16 in Costa Mesa, CA! Together, we’re committed to supporting and empowering adults with disabilities. To learn more about the conference, visit ndss.org/adult-summit.

A newly released RAND report commissioned in partnership with BrightFocus Foundation, Alliance for Aging Research, and National Down Syndrome Society shows that boosting research investment into the health and wellbeing of adults with Down syndrome would improve their quality-of-life outcomes, reduce caregiving costs, and extend the lifespan of adults with Down syndrome. “This report illustrates conclusively that early investment in care and treatment will have a meaningful impact on the health, wellness, and longevity of adults with Down syndrome,” Hampus Hillerstrom, president and CEO of LuMind IDSC said. “Not only are the conclusions of this report important to note, but the data itself will be of use to researchers, foundations, and pharmaceutical and biotech companies that may be considering research into the significant medical needs of adults with Down syndrome.” Learn more and find the full report online: https://lnkd.in/e5DwgaVf

We envision a world where every person with Down syndrome thrives with improved health, independence, and opportunities to reach their fullest potential. October is Down Syndrome Awareness Month, so we invite you to join us as we raise awareness about Down syndrome and the accomplishments and abilities of individuals with Down syndrome! #Downsyndromeawareness

Do you know an employee or volunteer of a Down syndrome non-profit organization who embodies kindness without judgment to make a difference in the world? The Collin Lis Humanitarian Award acknowledges exemplary Down Syndrome organization employees, advocates, or supporters who have consistently demonstrated compassion and kindness to others, just like Collin. In just 11 years, Collin made a very positive and life-long impact on his family, his friends, and the Down syndrome community. He was well known for his smile, hugs, unwavering kindness, and ability to brighten others’ days. His small acts of kindness helped make a difference in the world, and his family and friends remember Collin as a special and unique soul whose spirit will always inspire others. If you know someone making a difference in the Down syndrome community through kindness, be sure to make a nomination today! https://lnkd.in/gSBQCzwg #Downsyndrome #kindnessmatters

"My brother is healthy. My brother does not have signs of dementia. And he never will, because he just can’t. Not my brother. Not the person I love.? But there are moments when reality hits." Amit Das, LuMind IDSC Senior Manager of Strategy & Research, shares a personal reflection about his amazing brother with Down syndrome and the realities of Down syndrome-associated Alzheimer's Disease. https://lnkd.in/e9ZDu6Xp #Downsyndrome #DownSyndromeAssociatedAlzheimersDisease

LuMind IDSC was excited to be a part of the #AAIC2024 in Philadelphia over the past few days to learn more about recent advancements in dementia research. A special thank you to our exhibiting partner, The Rainwater Charitable Foundation, for joining us at this important conference!

On this date 34 years ago, July 26, 1990, the Americans with Disabilities Act (ADA) was signed into law. This important civil rights law prohibits discrimination against individuals with disabilities in all areas of public life. Today, as we commemorate the anniversary of the #ADA, we look to the future. We will continue our mission to accelerate research to increase the availability of therapeutic, diagnostic, and medical care options and empower families through education, connections, and support so that every person with Down syndrome thrives with improved health, independence, and opportunities to reach their fullest potential. #AmericanswithDisabilitiesAct #downsyndrome #NationalDisabilityIndependenceDay #DisabilityPrideMonth

Have you heard? Mount Sinai recently secured over $4 Million in a grant from the National Institutes of Health to study Alopecia Areata and Atopic Dermatitis in People With Down Syndrome. “Given how common inflammatory skin diseases are in this population, particularly atopic dermatitis and alopecia areata, we want to ensure that safe and effective treatments are available, and that we understand the effects that they have on immune modulation in people with Down syndrome,” said Dr. Emma Guttman. Read more about this first-of-its-kind clinical trial: https://bit.ly/3Sgo6HU

BREAKING NEWS: "Every new treatment option that becomes available for Alzheimer’s disease is critically important for the Down syndrome community.” Yesterday, the FDA approved Eli Lilly and Company's new Alzheimer's treatment drug, now called Kisunla. Read on for information about this new drug and the impact on people with Down syndrome and their families. https://lnkd.in/g6-Gs_qT

The day we have been waiting for! A major pharmaceutical company has announced that the Down syndrome population will see a clinical trial of a new Alzheimer’s drug. People with Down syndrome will be invited to participate in a clinical trial of donanemab, the anti-amyloid Alzheimer’s drug developed by Eli Lilly and Company (Lilly). The news was announced in comments by Lilly’s Chief Medical Officer, David Hyman, MD, during a U.S. Food & Drug Administration (FDA) Advisory Committee meeting on the status of the drug. Read more online: https://lnkd.in/esbnXFVv #DownSyndrome #AlzheimersDisease #DownSyndromeResearch